앱클론

174900KOSDAQ의료용품 및 기타 의약 관련제품 제조업

56.8 / 100

Reference Date: 2026-06-10

Financial Score18.5 / 40

News Sentiment21.3 / 25

Momentum5.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 31.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Appclone is a biotech company specializing in the development of monoclonal antibody-based pharmaceuticals. It focuses on creating 'Biosynergy' drugs that enhance efficacy when combined with existing medications and 'Biounique' antibodies with distinct mechanisms of action for monotherapy. The company also leverages its 'Affibody' technology and human antibody library to develop innovative treatment solutions.

Number of Employees

66people

Average Salary

57.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.194.0Point

PBR

10.15Industry Average 1.300.0Point

7.8x industry avg (risky)

ROE

-39.86Industry Average -4.893.5Point

8.2x industry avg (excellent)

Debt Ratio

1.58Industry Average 6.868.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼23.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -45.9% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Positive
이종서 앱클론 대표 “HLX22로 항체 기술 입증…인비보 CAR-T로 ...
앱클론 대표의 HLX22 항체 기술 성공 발표로 인해 회사의 기술력과 미래 성장 가능성이 긍정적으로 평가됨.
Positive
앱클론 “기술이전 위암 치료제, 글로벌 3상 첫 환자 투약 완료”
앱클론의 기술이전 위암 치료제가 글로벌 3상 임상 시험에서 첫 환자 투약을 성공적으로 완료하며 긍정적인 시장 반응을 이끌어냈다.
Positive
앱클론, 식약처와 4억여원 규모 시약·기자재 공급 계약
앱클론이 식약처와의 계약으로 추가 자금 확보 및 연구개발 활동 강화 기대.

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 30,750Won52-week high 89,10052-week low 9,890

1-month return0.0Point

1m -31.13% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 1Neutral 1Negative 0

Positive단일판매ㆍ공급계약체결(자율공시)2026-05-21
Neutral분기보고서 (2026.03)2026-05-15